FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1570721654> ?p ?o ?g. }

• W1570721654 endingPage "1905" @default.
• W1570721654 startingPage "1899" @default.
• W1570721654 abstract "Study Type – Therapy (outcomes research) Level of Evidence 2b OBJECTIVE • To determine oncological outcomes after high‐intensity focused ultrasonography (HIFU) treatment in patients with localized prostate cancer using a new, more accurate, definition (‘Stuttgart’ definition) of biochemical failure. PATIENTS AND METHODS • We performed a retrospective review of all patients in our centre who received first‐line treatment with a second‐generation Ablatherm TM device (EDAP‐TMS, Lyon, France). • Oncological failure was given either by biochemical failure (prostate‐specific antigen, PSA, nadir plus 1.2 g/mL) (Stuttgart definition) or the start of salvage therapy because of a persistently positive biopsy after the HIFU procedure. • The 5‐year biochemical‐free survival rate and 5‐year disease‐free survival rate were calculated. RESULTS • In total, 53 patients were included (mean age, 72.5 ± 4.5 years, range 60–79 years; 28 low risk and 25 intermediate risk). None had undergone previous hormonal therapy. Mean ± sd follow‐up was 45.4 ± 15.5 months (range 16–71 years). Mean (range) pre‐treatment PSA was 8.5 ± 4 (0.29–18) ng/mL. The median (range) PSA nadir value was 1 (0.01–14) ng/mL and occurred after a mean (range) of 5.09 (3–24) months. • Overall, 36 patients (67.9%) experienced oncological failure. • These included 33 cases (62.2%) of biochemical failure. A PSA nadir of ≤0.2, 0.21–1.0 and >1 ng/mL was reached in 20.8%, 30.2% and 49% of patients, respectively, and was associated with biochemical failure in 9.1%, 30.3% and 60.6%, respectively. • The 5‐year biochemical‐free survival rate and disease‐free survival rate were 21.7% and 13.5%, respectively. In multivariate analysis, a PSA nadir of >1 ng/mL was significantly associated with a risk of biochemical and oncological failure ( P = 0.002 and P < 0.001). • Oncological failure was not associated with any risk group. • No patient died from prostate cancer. CONCLUSIONS • In our experience, Ablatherm TM treatment for clinically localized prostate cancer was associated with a high rate of biochemical failure as determined by the ‘Stuttgart’ definition, and did not achieve effective cancer control. • The PSA nadir value after HIFU treatment was a significant predictor of treatment failure." @default.
• W1570721654 created "2016-06-24" @default.
• W1570721654 creator A5007519169 @default.
• W1570721654 creator A5011830520 @default.
• W1570721654 creator A5026630249 @default.
• W1570721654 creator A5031665859 @default.
• W1570721654 creator A5041028457 @default.
• W1570721654 creator A5044391134 @default.
• W1570721654 creator A5046745107 @default.
• W1570721654 creator A5066149785 @default.
• W1570721654 creator A5090689926 @default.
• W1570721654 date "2010-11-17" @default.
• W1570721654 modified "2023-10-18" @default.
• W1570721654 title "Six years’ experience with high-intensity focused ultrasonography for prostate cancer: oncological outcomes using the new ‘Stuttgart’ definition for biochemical failure" @default.
• W1570721654 cites W1965717154 @default.
• W1570721654 cites W1984222175 @default.
• W1570721654 cites W1997394967 @default.
• W1570721654 cites W2011874271 @default.
• W1570721654 cites W2014639327 @default.
• W1570721654 cites W2020762361 @default.
• W1570721654 cites W2023117080 @default.
• W1570721654 cites W2023913024 @default.
• W1570721654 cites W2040538815 @default.
• W1570721654 cites W2051035889 @default.
• W1570721654 cites W2058126130 @default.
• W1570721654 cites W2058730737 @default.
• W1570721654 cites W2063456541 @default.
• W1570721654 cites W2069948953 @default.
• W1570721654 cites W2093867637 @default.
• W1570721654 cites W2100342702 @default.
• W1570721654 cites W2103046747 @default.
• W1570721654 cites W2105454326 @default.
• W1570721654 cites W2123230901 @default.
• W1570721654 cites W2128331182 @default.
• W1570721654 cites W2129806101 @default.
• W1570721654 cites W2138099766 @default.
• W1570721654 cites W2140402608 @default.
• W1570721654 cites W2141283971 @default.
• W1570721654 cites W2160612556 @default.
• W1570721654 cites W3147941944 @default.
• W1570721654 cites W4239319701 @default.
• W1570721654 cites W4377834532 @default.
• W1570721654 doi "https://doi.org/10.1111/j.1464-410x.2010.09710.x" @default.
• W1570721654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21083637" @default.
• W1570721654 hasPublicationYear "2010" @default.
• W1570721654 type Work @default.
• W1570721654 sameAs 1570721654 @default.
• W1570721654 citedByCount "22" @default.
• W1570721654 countsByYear W15707216542012 @default.
• W1570721654 countsByYear W15707216542013 @default.
• W1570721654 countsByYear W15707216542014 @default.
• W1570721654 countsByYear W15707216542015 @default.
• W1570721654 countsByYear W15707216542016 @default.
• W1570721654 countsByYear W15707216542018 @default.
• W1570721654 countsByYear W15707216542019 @default.
• W1570721654 countsByYear W15707216542020 @default.
• W1570721654 countsByYear W15707216542021 @default.
• W1570721654 countsByYear W15707216542022 @default.
• W1570721654 crossrefType "journal-article" @default.
• W1570721654 hasAuthorship W1570721654A5007519169 @default.
• W1570721654 hasAuthorship W1570721654A5011830520 @default.
• W1570721654 hasAuthorship W1570721654A5026630249 @default.
• W1570721654 hasAuthorship W1570721654A5031665859 @default.
• W1570721654 hasAuthorship W1570721654A5041028457 @default.
• W1570721654 hasAuthorship W1570721654A5044391134 @default.
• W1570721654 hasAuthorship W1570721654A5046745107 @default.
• W1570721654 hasAuthorship W1570721654A5066149785 @default.
• W1570721654 hasAuthorship W1570721654A5090689926 @default.
• W1570721654 hasConcept C121608353 @default.
• W1570721654 hasConcept C126322002 @default.
• W1570721654 hasConcept C126894567 @default.
• W1570721654 hasConcept C141071460 @default.
• W1570721654 hasConcept C167135981 @default.
• W1570721654 hasConcept C2775934546 @default.
• W1570721654 hasConcept C2776235491 @default.
• W1570721654 hasConcept C2778311097 @default.
• W1570721654 hasConcept C2780192828 @default.
• W1570721654 hasConcept C71924100 @default.
• W1570721654 hasConceptScore W1570721654C121608353 @default.
• W1570721654 hasConceptScore W1570721654C126322002 @default.
• W1570721654 hasConceptScore W1570721654C126894567 @default.
• W1570721654 hasConceptScore W1570721654C141071460 @default.
• W1570721654 hasConceptScore W1570721654C167135981 @default.
• W1570721654 hasConceptScore W1570721654C2775934546 @default.
• W1570721654 hasConceptScore W1570721654C2776235491 @default.
• W1570721654 hasConceptScore W1570721654C2778311097 @default.
• W1570721654 hasConceptScore W1570721654C2780192828 @default.
• W1570721654 hasConceptScore W1570721654C71924100 @default.
• W1570721654 hasIssue "12" @default.
• W1570721654 hasLocation W15707216541 @default.
• W1570721654 hasLocation W15707216542 @default.
• W1570721654 hasOpenAccess W1570721654 @default.
• W1570721654 hasPrimaryLocation W15707216541 @default.
• W1570721654 hasRelatedWork W151774199 @default.
• W1570721654 hasRelatedWork W2075763133 @default.
• W1570721654 hasRelatedWork W2088520467 @default.
• W1570721654 hasRelatedWork W209797606 @default.
• W1570721654 hasRelatedWork W2376423713 @default.

• next